J. W. Goldman Et Al. , "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN," ESMO Virtual Congress , vol.31, ELECTR NETWORK, 2020
Goldman, J. W. Et Al. 2020. Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. ESMO Virtual Congress , (ELECTR NETWORK).
Goldman, J. W., Garassino, M. C., Chen, Y., Reinmuth, N., Hotta, K., Poltoratskiy, A., ... Trukhin, D.(2020). Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN . ESMO Virtual Congress, ELECTR NETWORK
Goldman, J. Et Al. "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN," ESMO Virtual Congress, ELECTR NETWORK, 2020
Goldman, J. W. Et Al. "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN." ESMO Virtual Congress , ELECTR NETWORK, 2020
Goldman, J. W. Et Al. (2020) . "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN." ESMO Virtual Congress , ELECTR NETWORK.
@conferencepaper{conferencepaper, author={J. W. Goldman Et Al. }, title={Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN}, congress name={ESMO Virtual Congress}, city={}, country={ELECTR NETWORK}, year={2020}}